Earnings Preview: Incyte to Report Financial Results Pre-market on April 29
J.P. Morgan Maintains Incyte(INCY.US) With Hold Rating, Announces Target Price $68
Incyte Is Maintained at Neutral by JP Morgan
Incyte Analyst Ratings
JPMorgan Adjusts Incyte Price Target to $68 From $70, Maintains Neutral Rating
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $87
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $87
Investors in Incyte (NASDAQ:INCY) Have Unfortunately Lost 43% Over the Last Five Years
BofA Adjusts Price Target on Incyte to $87 From $86, Keeps Buy Rating
Top SA Quant-rated Healthcare Stocks as Q1 Earnings Unfold
Incyte Corp. Stock Advances 4.1%, Outperforms Competitors
Notable Healthcare Headlines of the Week: Norvatis, Novo Nordisk, Eli Lilly in Focus
Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says
Press Release: Incyte to Report First Quarter Financial Results
UBS Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $61
Incyte Price Target Lowered to $61 From $69 at UBS
J.P. Morgan Maintains Incyte(INCY.US) With Hold Rating
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
J.P. Morgan Sticks to Their Hold Rating for Incyte (INCY)